Shanghai Hansoh Biomedical Co.Ltd
HS-20093 (Phase Ia: Dose escalation)(Shanghai Hansoh Biomedical Co., Ltd)은 Advanced Solid Tumor 표적 ADC로, Advanced Solid Tumor 영역에서 개발·상용화 중입니다. 작용기전: targeting the vascular endothelial growth factor receptor. Phase 1 안전성·PK 탐색 단계입니다. ClinicalTrials.gov 기준 79건의 관련 임상이 등록되어 있습니다. 차별점: novel HER2-selective tyrosine kinase inhibitor that spares epidermal growth factor receptor, in patients with HER2-altered so.
Advanced Solid Tumor
Advanced Solid Tumor
Active
ADC) GQ1001 was assessed in patients with previously treated HE
GQ1001
adenoviral vector engineered to express an agonist anti-cluster of differentiation (CD)40
novel HER2-selective tyrosine kinase inhibitor that spares epidermal growth factor receptor, in patients with HER2-altered so
targeting the vascular endothelial growth factor receptor
T cell recruitment
payload of GQ1001, was quantitated
HER2 antibody-drug conjugate GQ1001 in patients with previously treated HER2 positive
Downregulation of KRAS G12D DNA and suppression of phospho-Erk was documented together with an increase in intratumoral CD8 + T cells
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Shanghai Hansoh Biomedical Co.Ltd
HS-20093 (Phase Ia: Dose escalation)(Shanghai Hansoh Biomedical Co., Ltd)은 Advanced Solid Tumor 표적 ADC로, Advanced Solid Tumor 영역에서 개발·상용화 중입니다. 작용기전: targeting the vascular endothelial growth factor receptor. Phase 1 안전성·PK 탐색 단계입니다. ClinicalTrials.gov 기준 79건의 관련 임상이 등록되어 있습니다. 차별점: novel HER2-selective tyrosine kinase inhibitor that spares epidermal growth factor receptor, in patients with HER2-altered so.
Advanced Solid Tumor
Advanced Solid Tumor
Active
ADC) GQ1001 was assessed in patients with previously treated HE
GQ1001
adenoviral vector engineered to express an agonist anti-cluster of differentiation (CD)40
novel HER2-selective tyrosine kinase inhibitor that spares epidermal growth factor receptor, in patients with HER2-altered so
targeting the vascular endothelial growth factor receptor
T cell recruitment
payload of GQ1001, was quantitated
HER2 antibody-drug conjugate GQ1001 in patients with previously treated HER2 positive
Downregulation of KRAS G12D DNA and suppression of phospho-Erk was documented together with an increase in intratumoral CD8 + T cells
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.